Kishu Ranjan

Dr. Kishu Ranjan is an Associate Research Scientist in Pathology at Yale University School of Medicine, specializing in cancer cell signaling and immunobiology. His research focuses on HLA class I antigen presentation machinery (APM) dysfunction in tumor immune evasion and immunotherapy resistance, with contributions to biomarker discovery for non-small cell lung cancer (NSCLC). He holds a PhD from the M.S. University of Baroda, India, and completed postdoctoral training at Yale.

Education & Training:

• Postdoctoral Fellowship, Yale University
• PhD, Biochemistry, M.S. University of Baroda, India
• MS, Biochemistry, M.S. University of Baroda, India

Research Interests: Dr. Ranjan’s work centers on molecular mechanisms of immune evasion in cancer, including TAP2 deficiency’s role in PD-1/PD-L1 immunotherapy resistance. His lab explores restoring APM function through drug screening and developing biomarkers predictive of treatment response. Key areas include ER stress pathways, innate immunity regulation, and translational applications of biomarkers in NSCLC.

Publications Trends: His 15 most recent articles highlight studies on TAP2 downregulation mechanisms, HLA APM alterations in brain metastases, RNF186’s role in ER stress signaling, and translational research on SARS-CoV-2 variants. These contributions bridge basic science and clinical oncology, emphasizing immune-oncology and targeted therapies.

Awards:

• Young Investigator Travel Award (SITC, 2022)
• Senior Research Fellowship (ICMR, 2012)
• Young Investigator Travel Award (DBT, India, 2013)

Lab & Collaborations: Based in the Schalper Lab, he collaborates with clinicians and researchers on tumor immunology projects. Ongoing initiatives include screening compounds to restore TAP2 expression and evaluating biomarkers for immunotherapy efficacy.